Pfizer ends danuglipron development after liver safety issue, boosting shares of Viking, Eli Lilly, and Novo Nordisk amid ...

Once-daily orforglipron was more effective than placebo and just as safe as injectable GLP-1s in patients with diabetes and ...

A new oral GLP-1 drug candidate could transform the diabetes and weight loss drug boom. Why it matters: Eli Lilly said on ...

Objective: To review drug interaction studies of glucagon-like peptide-1 receptor agonists (GLP-1RAs) and concurrent oral medications. Data Sources: PubMed was searched (to December 5, 2011 ...

Shares of Viking Therapeutics (VKTX) and Structure Therapeutics (GPCR) are on the rise on Monday after Pfizer (PFE) announced its decision to discontinue development of danuglipron, an oral ...

Structure Therapeutics Inc.’s GPCR share price has surged by 29.14%, which has investors questioning if this is right time to sell.

The rapid increase in the use of glucagon-like peptide-1 receptor agonists for weight loss, diabetes management and ...

Pfizer’s announcement that it will stop developing its oral weight-loss drug gave shares of Wegovy maker Novo Nordisk and ...

Five scientists won this year’s Breakthrough Prize in Life Sciences for their work on GLP-1 and the development of drugs for diabetes and obesity.

Shares of Eli Lilly (LLY) jumped on Thursday morning after the company announced topline Phase 3 results from ACHIEVE-1, evaluating the safety ...

most likely drawn from the glucagon-like peptide 1 class of drugs. As I wrote in my last note on Structure: The most famous examples of GLP-1 agonist drugs are Novo Nordisk's (NVO) semaglutide ...

Lilly's weight-loss drug trial shows promising results, propelling stock up 14.36%. Goldman Sachs predicts potential $23.5B in sales by 2035.